A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus

Trial Profile

A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs 514 G3 (Primary)
  • Indications Staphylococcal infections
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors XBiotech
  • Most Recent Events

    • 03 Apr 2017 According to an XBiotech media release, Dr. Mark E. Rupp, Professor and Chief, Division of Infectious Diseases, Medical Director, Department of Infection Control & Epidemiology at the University of Nebraska is the principal investigator in this trial.
    • 03 Apr 2017 Top-line results published in a XBiotech media release.
    • 16 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top